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GRAPHICAL ABSTRACT: 
 
 
ABSTRACT: The dicyclohexylborane–mediated addition of allene 1 to (E)-2-tridecenal 
affords a quaternary protected 2-amino-2-vinyl-1,3-diol in good yield as a single 
diastereomer. This compound is readily transformed into the four stereoisomers of the 
quaternary (E)-2-vinyl analogs of sphingosine. The metabolic fate and the effect of these 
compounds on the basal sphingolipid metabolism in human A549 lung adenocarcinoma cells 
has been studied, together with the ceramide analog of the most relevant vinylsphingosine 
derivative. 
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Introduction 
Sphingolipids are a family of natural products that play essential roles as structural cell 
membrane components and also in cell signaling through a complex metabolic network 
involving specific enzymes. From a structural point of view, most mammalian sphingolipids 
share a common 2-amine-1,3-diol moiety arising from (E)-2-amino-4-octadecen-1,3-diol 
(sphingosine). Interestingly, some structural analogs of sphingosine and/or ceramides (N-acyl 
sphingosines) can act as selective inhibitors of sphingolipid metabolism enzymes and they 
exhibit interesting pharmacological properties.1–3 In particular, Boumendjel and Miller 
reported that compound 2 (Figure 1, mixture of isomers), a quaternary vinyl analog of 
dihydrosphingosine 1-phosphate, exhibits potent inhibition of sphingosine 1-phosphate lyase.4 
Based on the above precedents, it is conceivable that the introduction of the 2-amino-2-vinyl-
1,3-diol core as part of the sphingolipid framework represents an attractive modification for 
the design of new modulators of sphingolipid metabolism. In this work, we present an 
adaptation of our previously reported protocol5 to the enantioselective synthesis of quaternary 
2-vinyl sphingosines 9 (Figure 1). In addition, studies on their cellular metabolism, cellular 
toxicity and effects on basal sphingolipid metabolism in human A549 lung adenocarcinoma 
cells are discussed. 
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Fig. 1 Sphingolipids, 2-vinyl dihydrosphingosine 1-phosphate (2), and 2-vinylsphingosines (9) 
 
Results and discussion 
Chemistry 
We recently reported a highly stereoselective addition of N-tosyl allene 3 to aldehydes leading 
to protected tosylcarbamates (±)-4.5 This one-pot process is based on the hydroboration of the 
allene with (c-C6H11)2BH at the less hindered face of the terminal double bond to generate an 
allylborane which could be added in situ to an aldehyde (Scheme 1). However, in practice, the 
use of tosyl as N-protecting group suffers from some drawbacks. First, the robust tosyl group 
may be difficult to remove in the final steps of a multi-step synthetic sequence. Secondly, the 
N-tosyl group favors an facile acid or base-catalyzed partial isomerization to the 
corresponding inner N-tosylcarbamates 5 during work-up and/or chromatographic purification 
of compounds 4, leading to mixtures that are difficult to separate. 
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Scheme 1 Preparation of N-tosylcarbamates (±)-4 and their isomerization to (±)-5 
These disadvantages can be avoided almost completely by using allene 1 (Scheme 2), 
obtained from but-2-yn-1,4-diol in 61% yield,6 in which the more easily removable N-benzoyl 
group is used as protecting group.7 We envisaged that the addition of allene 1 to (E)-2-
tridecenal would provide access to 2-vinyl sphingoid analogs 9 (Figure 1), structurally related 
to sphingosine. Considering the incorporation of the vinyl unit in 9, the use of (E)-2-
tridecenal would afford a C17 long chain base, which is expected to be endowed with 
appropriate properties for cell permeabilization. As expected, hydroboration of 1 with (c-
C6H11)2BH, in CH2Cl2 at 0 ºC followed by addition of (E)-2-tridecenal, afforded carbamate 
(±)-6 in very high diastereochemical purity (>95:5 by 1H NMR) after a hydrolytic work-up 
with triethanolamine and column chromatography. It should be remarked that complete 
migration of the benzoyl protecting group from the nitrogen atom to the newly formed 
secondary alcohol was observed, in this way avoiding the isomerization of 6 to the inner 
carbamate (±)-7’ (Scheme 2), as was observed in the isomerization of 4 into 5 (Scheme 1). 
Thus, compound (±)-6 was obtained in an acceptable 75% yield, after chromatographic 
purification, as a single diastereomer (as racemic mixture of both enantiomers). 
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Scheme 2 Synthesis of sphingoid precursor (±)-7 from allene 1 and attempts of selective hydrolysis of 
benzoate (±)-6  
 
Hydrolysis of the benzoate group in (±)-6 to the desired alcohol (±)-7 avoiding isomerization 
to the inner carbamate was not a trivial task. A number of hydrolytic treatments with different 
basic (K2CO3, LiOH) or acidic (H2SO4, HCl) aqueous or methanolic media, as well as 
reductive treatment of (±)-6 with LiBH4 in THF, were performed leading to mixtures of both 
carbamates arising from the primary or the secondary alcohol ((±)-7 and (±)-7'). Gratifyingly, 
the use of EtMgBr in THF at 0 ºC afforded the required alcohol (±)-7 in good yield with 
negligible isomerization. Since we were interested in the influence of the different 
stereoisomers of 2-vinyl sphingosines in sphingolipid metabolism, we undertook the 
resolution of (±)-7. This was accomplished by transformation of (±)-7 into a mixture of the 
corresponding diastereomeric esters 8 derived from (R)-methoxyphenylacetic acid [(R)-
MPA]8 using EDC as coupling reagent in the presence of a catalytic amount of DMAP. Esters 
8 were then easily isolated by column chromatography and their configuration at C3 was 
inferred from Δδ between selected pair of protons, following the empirical method of Riguera 
et al,9 as indicated in Table 1. Since the relative configuration between C2 and C3 had already 
been established based on mechanistic grounds,5 the absolute configuration at both 
stereogenic centers in esters 8 was thus assigned. 
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3S configuration assigned from Δδ [(2R,3S) or (2S,3R)] (R)-MPA esters 
 δHC(*) δHD(*) δHE δHF δHG(*) δHH δHI(*) δHJ 
2R3S 1.16 1.88 5.59 5.18 5.83 5.28 4.11 5.90 
2S3R 1.29 2.02 5.91 5.30 5.62 5.06 3.85 5.72 
ΔδSR -0.13 -0.14 -0.32 -0.12 +0.21 +0.22 +0.26 +0.18 
3R configuration assigned from Δδ [(2R,3R) or (2S,3S)] (R)-MPA esters 
 δHC(*) δHD(*) δHE δHF δHG(*) δHH δHI(*) δHJ 
2R3R 1.32 2.01 5.82 5.29 5.62 5.16 3.90 5.42 
2S3S 1.01 1.80 5.24 5.09 5.81 5.34 4.17 5.78 
ΔδRS +0.31 +0.21 +0.58 +0.20 -0.19 -0.18 -0.27 -0.36 
(*) δ from the center of the system 
Table 1: Configurational assignment at C3 position of (R)-MPA esters 8 
 
Enantiopure (2S,3R)-8 and (2R,3S)-8 we independently treated in basic aqueous-alcoholic 
media to obtain free aminodiols (2S,3R)-9 and (2R,3S)-9, respectively, in good yields 
(Scheme 3). 
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Scheme 3 Resolution of (±)-7 and conversion of enantiopure esters 8 into (2S,3R)-9 and (2R,3S)-9 
 
Regarding the preparation of the enantiomeric series, (2S,3S) and (2R,3R), we first attempted 
a direct inversion of the secondary alcohol in (±)-7 by Mitsunobu reaction, using benzoate as 
nucleophile, without success. We then turned our attention to a redox two-step process based 
on the oxidation of (±)-7 to ketone (±)-11, followed by reduction. In practice, the Dess-Martin 
oxidation of (±)-7 gave ketone (±)-11, which was used without further purification. The 
reduction of (±)-11 under Luche conditions (Ce(III)/NaBH4)10 turned out to be only 
minimally stereoselective, since a roughly 1:1 mixture of the corresponding diastereomeric 
alcohols in a satisfactory 63% yield (over two steps) was obtained (Scheme 4). Unfortunately, 
we were not able to efficiently isolate both diastereomeric racemates by column 
chromatography. Thus, we attempted the resolution of the mixture of alcohols through the 
formation of the corresponding diastereomeric esters 8 derived from (R)-MPA (Scheme 4). 
To our satisfaction, the four stereoisomeric esters exhibited sufficient separation by TLC. 
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After column chromatographic isolation of (2R,3R)-8 and (2S,3S)-8, the amino diols (2R,3R)-
9 and (2S,3S)-9 were obtained in 85% and 65% yield, respectively, by basic hydrolysis. 
Again, the configuration at C3 of the diasteromeric esters (2R,3R)-8 and (2S,3S)-8 was 
inferred by the method of Riguera et al, based on the Δδ values indicated in Table 1. 
 
Scheme 4 Resolution of (±)-11 and preparation of (2S,3S) and (2R,3R) 8 and 9. 
 
Metabolism of amino diols 9. 
Treatment of A549 cells with sub-toxic concentrations (Fig. S1) of amino diols 9 revealed 
that only the 2S,3R stereomer was N-acylated (Fig. 2A,B). Interestingly, only the C22, C24 
and C24:1 acyl derivatives were formed (Fig. 2A). Since A549 cells also produce ceramides 
with other N-acyl chains, with C16 being also abundant11,12 (See Figure 3), this result 
suggests that (2S,3R)-9 is a substrate of ceramide synthase 2 (CerS2), which produces long 
chain ceramides, but it is not a good substrate of CerS5 and CerS6, which catalyze the 
formation of C16 ceramide.13 This is the first example of a sphingoid base selectively used by 
a specific CerS. On the other hand, only (2S,3R)-9 and, to a significantly lower extent, 
(2S,3S)-9 are phosphorylated at C1OH (Figure 2B), which supports the idea that, despite the 
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presence of the vinyl group, sphingosine kinase activity takes place preferentially on the 2S 
stereoisomer. Importantly, the above long chain N-acyl derivatives of (2S,3R)-9 were 
metabolically stable, as neither the sphingomyelin analogs nor the glucosylceramide analogs 
were detected in the extracts.  
To investigate the metabolic stability of amides of (2S,3R)-9 against ceramidases, N-
octanoylamide 10, obtained by acylation of (2S,3R)-9 with octanoic acid (EDC/DMAP), was 
incubated with A549 cells at sub-toxic concentrations (Figure S1). As shown in Figure 2C, 
the free base (2S,3R)-9 was detected in the extracts. Furthermore, the C22, C24 and C24:1 
acyl derivatives of (2S,3R)-9 were also formed (Figure 2D), indicating that amide 10 is 
hydrolyzed by ceramidases and further reacylated with other acyl moieties. However, which 
of the 5 different ceramidases13 is responsible for the hydrolysis of (2S,3R)-10 is, so far, 
unknown. 
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Fig. 2 Metabolism of compounds 9 and (2S,3R)-10 . Cells were incubated with: A-B, the four 
stereoisomers of 9 (15 µM) and C-D, amide (2S,3R)-10 (30 µM) for 24 h. Lipid analysis was 
carried out by UPLC/TOF MS in ESI + (free bases and amides) or ESI – (phosphates). A-B, 
amounts of amides (A) and phosphates (B) present in cells treated with the different 
stereoisomers of 9; (C): amounts of incorporated amide (2S,3R)-10 and of its hydrolysis 
product (2S,3R)-9; (D): reacyclation products present in cells treated with amide (2S,3R)-10. 
Data were obtained from two independent experiments with triplicates.  
 
Effect on natural sphingolipids 
Cells treated with amino diols 9 did not give rise to any remarkable change in the natural 
sphingolipids content (data not shown). In contrast, cells exposed to amide (2S,3R)-10 (30 
µM/24 h) contained significantly lower total ceramide levels than vehicle treated controls, all 
the different N-acyl species being similarly reduced (Figure 3A). This reduction is translated 
into significantly lower levels of glucosylceramide (GlcCer) (Fig. 3B) and sphingomyelin 
(SM) (Fig. 3C). 
 
Fig. 3 Effect of (2S,3R)-10 on natural sphingolipids. Cells were incubated with (2S,3R)-10 
(30 µM/24 h). Lipids were extracted and analyzed by UPLC/TOF MS. (A): amounts of 
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natural ceramides (Cer); (B): amounts of natural glucosyl ceramides (GlcCer) and (C): 
amounts of natural sphingomyelins (SM). Data were obtained from 2 independent 
experiments with triplicates. Asterisks indicate statistical difference with vehicle (control) 
(P<0.05. Unpaired, two-tail t test). 
 
These results are consistent with inhibition of ceramide synthesis de novo. Since no increase 
in dihydroceramides was observed upon treatments (data not shown), dihydroceramide 
desaturase is not a likely candidate for inhibition. On the other hand, a decrease in CerS 
activity results in an increase in long chain bases and their phosphates.14,15 However, either 
sphinganine, sphingosine or their corresponding phosphates were not detected in extracts after 
cell treatment with amide (2S,3R)-10, arguing against inhibition of CerS. Furthermore, no 
accumulation of 3-ketosphinganine was found in extracts from cells incubated with (2S,3R)-
10, which is against inhibition of 3-ketosphinganine reductase. Therefore, we suggest that 
serine palmitoyl transferase (SPT), the rate-limiting enzyme in ceramide synthesis de novo, is 
the likely target of (2S,3R)-10. Although this amide is N-deacylated to (2S,3R)-9, this amino 
alcohol has no effect on Cer, GlcCer and SM levels, which argues against its involvement in 
the observed inhibition. Collectively, our data support that (2S,3R)-10 could be responsible 
for the putative SPT inhibition. 
 
Conclusions 
The first stereoselective preparation of the four stereoisomers of quaternary 2-vinyl analogs of 
sphingosine has been achieved in a small number of steps and the effect of these compounds 
on basal sphingolipid metabolism in human A549 lung adenocarcinoma cells has been 
studied. A stereoselective borane-mediated addition of allene 1 to (E)-2-tridecenal very 
recently developed in our research group was used, giving only a single diastereomer [(R,S)-7 
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and (S,R)-7]. Resolution of enantiomers was readily accomplished by chromatography of the 
corresponding mixture of (R)-MPA diastereomeric esters followed by basic hydrolysis. 
Among the 2-vinyl sphingosines, only the 2S,3R isomer was N-acylated to produce long chain 
ceramides, presumably by CerS2. The metabolic stability of these amides was studied with 
the corresponding (2S,3R)-N-octanoyl amide 10, which confirmed the operation of 
deacylation and reacylation metabolic pathways. Interestingly, the effects of amide 10 on 
natural sphingolipidome are in agreement with the inhibition of SPT, the first enzyme of the 
de novo biosynthesis of sphingolipids. 
 
Experimental section 
Chemistry 
All reactions involving moisture- or air-sensitive reagents were performed in oven-dried 
glassware under N2. Chemical shifts (δ) are quoted in parts per million and referenced for 1H 
NMR to internal TMS (for CDCl3) or residual solvent peak d 2.50 ppm (for DMSO-d6). 13C 
NMR are referenced to CDCl3 (d 77.0 ppm) or DMSO-d6 (d 39.5 ppm). Column 
chromatography was performed on silica gel (Merck 230-400 mesh). HRMS analyses were 
recorded on a LC/MSD-TOF mass spectrometer. 
 
3-Benzoyl-4-vinylideneoxazolidin-2-one (1). A solution of benzoyl isocyanate (4.20 g, 25.60 
mmol) in anhydrous CH2Cl2 (20 mL) was added to 2-butyn-1,4-diol (1.00 g, 11.60 mmol) at 0 
ºC under N2 atmosphere. The mixture was stirred for 5 hours at rt and the solvent was 
removed. A solution of Pd2(dba)3·CHCl3 (0.055 g, 0.05 mmol) in anhydrous THF (40 mL) 
and triethylamine (0.087 mL, 0.64 mmol) were added under N2 atmosphere. The mixture was 
stirred for 16 h at rt and filtered through a pad of Celite. The solid was washed with AcOEt. 
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The solvent was removed and the crude residue was purified by column chromatography 
(hexanes/AcOEt 4:1) to afford 0.595 g (61%) of allene 1. 
Compound 1, yellow solid; mp 102-103 ºC (lit.6 101.2-103 ºC); Rf (hexanes/AcOEt 2:1) = 
0.35; 1H NMR (400 MHz, CDCl3): δ 7.68 (m, 2H, ArH), 7.57 (m, 1H, ArH), 7.45 (m, 2H, 
ArH), 5.57 (t, 2H, J = 4.7 Hz, =CH2), 5.04 (t, 2H, J = 4.7 Hz, CH2O); 13C NMR (101 MHz, 
CDCl3): δ 193.6, 167.3, 151.9, 132.8, 129.2, 128.1, 128.0, 103.9, 90.4, 63.9; IR (film, cm-1): 
1792, 1689, 1331, 1308, 1157, 1068; HRMS (ESI+) calculated for C12H10NO3 [M+H]+ = 
216.0655, found = 216.0651. 
 
(RS,E)-1-[(2-oxo-4-vinyloxazolidin-4-yl]tridec-2-en-1-yl benzoate [(±)-6]. 
A solution of the allene 1 (1.24 g, 5.76 mmol, 1.00 eq) in anhydrous CH2Cl2 (4 mL) was 
added to a suspension of dicyclohexylborane16 (1.23 g, 6.91 mmol, 1.2 eq) in CH2Cl2 (6 mL) 
at 0 ºC and under nitrogen atmosphere. The resulting mixture was stirred for 10 min at 0 ºC 
and for 1 h at rt. The resulting solution was then cooled to – 78 ºC, and (E)- 2-tridecenal (1.58 
g, 8.06 mmol, 1.4 eq) was added. The reaction was stirred for 4 h at rt, and was then quenched 
by addition of triethanolamine (2.2 g, 2.5 eq). The resulting mixture was stirred for 1 h at rt. 
Evaporation of the solvent under vacuum gave a crude that was purified by flash column 
cromatography (hexanes/AcOEt 7:3) to afford 1.78 g (4.30 mmol, 75%) of adduct (±)-6. 
Compound (±)-6, yellow oil; Rf (hexanes/AcOEt 3:2) = 0.60; 1H NMR (400 MHz, CDCl3): 
δ 8.06-8.00 (m, 2H, ArH), 7.58-7.53 (m, 1H, ArH), 7.46-7.40 (m, 2H, ArH), 6.65 (bs, 1H, 
NH), 6.05-5.96 (m, 2H, =CH, CHOBz), 5.54-5.41 (m, 3H, =CHH, CH=CH), 5.34 (d, 1H, J = 
10.8 Hz, =CHH), 4.46 (d, 1H, J = 8.7 Hz, OCHH), 4.14 (d, 1H, J = 8.7 Hz, OCHH), 2.05 (td, 
2H, J = 7.9, 1.1 Hz, =CHCH2), 1.38-1.19 (m, 16H, C8H16), 0.87 (t, 3H, J = 6.9 Hz, CH3); 13C 
NMR (101 MHz, CDCl3): δ 165.4, 159.3, 140.6, 136.2, 133.5, 129.8, 129.7, 128.6, 121.8, 
117.3, 77.8, 72.2, 64.4, 32.5, 32.0, 29.7, 29.7, 29.5, 29.4, 29.3, 28.8, 22.8, 14.2; IR (ATR, cm-
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1): 3240, 2923, 1755, 1707, 1263, 709; HRMS (ESI+) calculated for C25H35NNaO4 [M+Na]+ 
= 436.2458, found = 436.2466. 
(RS,E)-4-(1-hydroxytridec-2-en-1-yl)-4-vinyloxazolidin-2-one [(±)-7].  
A 3M solution of EtMgBr in Et2O (1.3 mL, 3 eq) was dropwise added to a solution of 
compound (±)-6 (537 mg, 1.30 mmol, 1 eq) in dry THF (8 mL) at 0 ºC. The reaction was 
followed by TLC (hexanes/AcOEt 3:2). After 2 h at 0 ºC, the reaction was partitioned by 
addition of pH 7 buffer and CH2Cl2. The organic layer was washed with additional pH 7 
buffer solution, dried over MgSO4 and filtered. The evaporation of the solvent under vacuum 
gave a crude which was purified by flash column cromatography (hexanes/AcOEt 3:2) to 
afford compound (±)-7 (341 mg, 1.11 mmol, 85%): 
Compound (±)-7, mp = 70-2 ºC; Rf (hexanes/AcOEt 3:2) = 0.34; 1H NMR (400 MHz, 
CDCl3): δ 6.70 (bs, 1H, NH), 5.92 (dd, 1H, J = 17.3, 10.7 Hz, =CH), 5.80 (dt, 1H, J = 15.4, 
6.7 Hz, =CHCH2), 5.39-5.25 (m, 3H, CH=CH, =CH2), 4.44 (d, 1H, J = 8.5 Hz, OCHH), 4.05 
(d, 1H, J = 7.1 Hz, CHOH), 4.01 (d, 1H, J = 8.5 Hz, OCHH), 3.68 (bs, 1H, OH), 2.01 (q, 2H, 
J = 6.9 Hz, =CHCH2), 1.37-1.19 (m, 16H, C8H16), 0.85 (t, 3H, J = 6.9 Hz, CH3); 13C NMR 
(101 MHz, CDCl3): δ 160.2, 137.1, 136.9, 125.6, 116.4, 75.9, 71.7, 65.5, 32.5, 32.0, 29.7, 
29.5, 29.4, 29.3, 29.1, 22.7, 14.2; IR (ATR, cm–1): 3287, 2922, 2851, 1742, 1042, 936; 
HRMS (ESI+) calculated for C18H32NO3 [M+H]+ = 310.2377, found = 310.2384. 
 
(4SR,5RS,E)-5-(dodec-1-en-1-yl)-4-(hydroxymethyl)-4-vinyloxazolidin-2-one [(±)-7']. 
A solution of NaOH (0.04 g, 1.0 mmol) in 9:1 MeOH/H2O (1 mL) was added to a stirred 
solution of compound (±)-6 (300 mg, 0.73 mmol, 1 eq) in 9:1 MeOH/H2O (10 mL) at r.t. The 
advance of the reaction was followed by TLC (hexanes/AcOEt 3:2). After 6 h, the mixture 
was heated at 50 ºC for additional 3 h and no more changes was observed (TLC). The reaction 
was partitioned by addition of a saturated aqueous solution of NH4Cl (20 mL) and CH2Cl2 (20 
16		
mL). The phases were decanted and the aqueous phase was washed with more CH2Cl2 (2 x 10 
mL). The combined organic portions were dried over anhydrous MgSO4, filtered, and 
concentrated under reduced pressure. The residue was purified by column chromatography 
using silica gel (hexanes/AcOEt 7:3) to afford (±)-7' (0.112 g, 50%) and (±)-7 (0.072 g, 32%). 
Compound (±)-7': colourless oil; Rf (hexanes/AcOEt 3:2) = 0.18; 1H NMR (400 MHz, 
CDCl3): δ 6.70 (broad band, 1H, NH), 5.86 (dt, 1H, J = 15.2, 6.7 Hz, =CHCH2), 5.74 (dd, 1H, 
J = 17.4, 10.8 Hz, =CH), 5.72-5.66 (m, 1H, CH=CH), 5.37 (dd, 1H, J = 17.4, 0.5 Hz, =CHH), 
5.27 (dd, 1H, J = 10.8, 0.5 Hz, =CHH), 4.65 (d, 1H, J = 8.4 Hz, OCH), 3.71 (d, 1H, J = 12.0 
Hz, CHHOH), 3.56 (d, 1H, J = 12.0 Hz, CHHOH), 2.12-2.06 (m, 2H, =CHCH2), 1.29-1.23 
(m, 16H, C8H16), 0.87 (t, 3H, J = 6.5 Hz, CH3); 13C NMR (101 MHz, CDCl3): δ 160.3, 140.0, 
135.9, 121.7, 117.2, 86.6, 66.6, 64.6, 32.4, 32.0, 29.7, 29.7, 29.6, 29.5, 29.3, 28.9, 22.8, 14.2; 
IR (ATR, cm-1): 3277, 2922, 2853, 1736, 1350, 976; HRMS (ESI+) calculated for 
C18H32NO3 [M+H]+ = 310.2377, found = 310.2384. 
 
Isomerization of (±)-7 
A solution of Dess-Martin periodinane (DMP) (1.930 g, 4.414 mmol, 1.1 eq) in dry CH2Cl2 
(10 mL) was dropwise added to a stirred solution of (±)-7 (1.240 g, 4.007 mmol, 1 eq) in dry 
CH2Cl2 (10 mL) at r.t. The course of the reaction was followed by TLC. After 30 min, the 
reaction was quenched by adding sat. NaHCO3 aqueous solution (10 mL) and solid Na2S2O3 
(0.30 g). The mixture was extracted with CH2Cl2 (5 x 10 mL) and the combined organic 
layers were dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure 
to give 1.180 g of crude ketone (±)-11 [Rf (hexanes/AcOEt 3:2) = 0.58]. A mixture of NaBH4 
(0.443 g, 11.710 mmol, 3 eq) and CeCl3:7H2O (2.90 g, 7.807 mmol, 2 eq) was added to a 
solution of the crude ketone (1.180 g) in THF (20 mL) and EtOH (60 mL) at 0 ºC. After 6 h, 
the reaction was quenched by addition of a sat. solution of NH4Cl (40 mL) and water (60 
mL). The mixture was extracted with CH2Cl2 (5 x 20 mL) and the combined organic layers 
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were dried (MgSO4), filtered, and concentrated under reduced pressure. The 
1H NMR of the 
residue showed a roughly 1:1 mixture of isomers (±)-7 and its racemic diastereomer (0.781 g, 
2.44 mmol, 63% two-steps yield). 
 
Typical procedure for the preparation of the (R)-MPA esters 8. 
A solution of (R)-methoxyphenylacetic acid [(R)-MPA, 0.135 g, 0.81 mmol, 1.4 eq] and 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 0.167 g, 0.87 mmol) in CH2Cl2 (10 mL) 
was stirred at 0 ºC for 30 min. Then, a solution of (±)-7 (0.180 g, 0.58 mmol) and a catalytic 
amount of 4-dimethylaminopyridine (DMAP, 0.010 g) in CH2Cl2 (10 mL) was added and the 
solution was stirred for 2 h at r.t. The reaction was quenched by addition of 2M HCl (10 mL) 
and the organic phase was washed with more 2M HCl (10 mL), sat. NaHCO3 (10 mL) and 
brine (10 mL). The combined organic portions were dried over anhydrous MgSO4, filtered, 
and concentrated under reduced pressure. The crude product was purified by column 
chromatography in silica gel (4:1 hexanes/ EtOAc) to afford 0.117 g (0.27 mmol, 46%) of 
(2S,3R)-8 and 0.120 g (0.28 mmol, 47%) of (2R,3S)-8.  
(2S,3R)-8: colourless oil; Rf (hexanes/AcOEt 3:2) = 0.82; [α]D25 = +6.7 (c = 1.0, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 7.42-7.30 (m, 5H, ArH), 5.91 (dt, 1H, J = 14.7, 6.8 Hz, 
=CHCH2), 5.72 (bs, 1H, NH), 5.62 (dd, 1H, J = 17.3, 10.7 Hz, =CH), 5.36-5.23 (m, 2H, 
OCHCH=), 5.06 (d, 1H, J = 17.2 Hz, =CHH), 5.06 (d, 1H, J = 10.7 Hz, =CHH), 4.73 (s, 1H, 
CHPh), 3.96 (d, 1H, J = 8.8 Hz, OCHH), 3.75 (d, 1H, J = 8.8 Hz, OCHH), 3.38 (s, 3H, 
OCH3), 2.07-1.98 (m, 2H, =CHCH2), 1.38-1.19 (m, 16H, C8H16), 0.87 (t, 3H, J = 6.9 Hz, 
CH3); 13C NMR (101 MHz, CDCl3): δ 169.4, 158.4, 141.3, 136.2, 135.5, 129.1, 128.9, 127.3, 
121.3, 116.9, 82.5, 77.8, 72.0, 63.9, 57.5, 32.5, 32.0, 29.7, 29.7, 29.5, 29.5, 29.3, 28.7, 22.8, 
14.2; IR (ATR, cm-1): 2923, 2853, 1748, 1169, 1108, 752; HRMS (ESI+) calculated for 
C27H40NO5 [M+H]+ = 458.2901, found = 458.2913. 
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(2R,3S)-8: colourless oil; Rf (hexanes/AcOEt 3:2) = 0.69; [α]D25 = –71.0 (c = 1.0, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 7.42-7.32 (m, 5H, ArH), 5.90 (bs, 1H, NH), 5.83 (dd, 1H, J = 
17.2, 10.7 Hz, =CH), 5.59 (dt, 1H, J = 14.5, 6.8 Hz, =CHCH2), 5.33-5.26 (m, 3H, OCHCH=, 
=CH2), 5.22-5.13 (m, 1H, CH=CH), 4.76 (s, 1H, OCHPh), 4.23 (d, 1H, J = 8.8 Hz, OCHH), 
4.00 (d, 1H, J = 8.8 Hz, OCHH), 3.39 (s, 3H, OCH3), 1.94-1.87 (m, 2H, =CHCH2), 1.34-1.14 
(m, 16H, C8H16), 0.88 (t, 3H, J = 6.9 Hz, CH3); 13C NMR (101 MHz, CDCl3): δ 169.6, 158.4, 
140.6, 136.0, 135.9, 129.1, 128.8, 127.3, 120.8, 117.3, 82.6, 77.4, 71.8, 63.9, 57.5, 32.4, 32.1, 
29.8, 29.7, 29.5, 29.5, 29.2, 28.7, 22.8, 14.3; IR (ATR, cm-1): 2923, 2858, 1748, 1169, 1108, 
752; HRMS (ESI+) calculated for C27H40NO5 [M+H]+ = 458.2901, found = 458.2908. 
(2S,3S)-8: colourless oil; Rf (hexanes/AcOEt 3:2) = 0.40; [α]D25 = +6.5 (c = 1.0, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 7.50-7.31 (m, 5H, ArH), 5.81 (dd, 1H, J = 17.2, 10.7 Hz, 
CH2=CH), 5.78 (bs, 1H, NH), 5.39-5.30 (m, 3H, =CH2, CHOCO), 5.24 (dt, 1H, J = 15.6, 6.7 
Hz, =CHCH2), 5.09 (dd, 1H, J = 15.5, 6.0 Hz, CHCH=), 4.84 (s, 1H, CHOMe), 4.27 (d, 1H, J 
= 8.8 Hz, OCHH), 4.07 (d, 1H, J = 8.8 Hz, OCHH), 3.41 (s, 3H, OCH3), 1.80 (q, 2H, J = 6.0 
Hz, =CHCH2), 1.33-1.07 (m, 16H, C8H16), 0.88 (t, 3H, J = 6.8 Hz, CH3) 13C NMR (101 
MHz, CDCl3): δ 169.6, 158.9, 138.3, 136.0, 135.5, 129.0, 128.8, 127.5, 120.7, 117.4, 82.3, 
77.1, 64.0, 57.4, 32.3, 32.0, 29.8, 29.7, 29.5, 29.5, 29.1, 28.7, 22.8, 14.3; IR (ATR, cm-1): 
2923, 2853, 1748, 1169, 1108, 752; HRMS (ESI+) calculated for C27H40NO5 [M+H]+ = 
458.2901, found = 458.2895. 
(2R,3R)-8: colourless oil; Rf (hexanes/AcOEt 3:2) = 0.62; [α]D25 = –98.7 (c = 1.0, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 7.49-7.32 (m, 5H, ArH), 5.82 (dt, 1H, J = 15.2, 6.8 Hz, 
=CHCH2), 5.62 (dd, 1H, J = 17.2, 10.7 Hz, CH2=CH), 5.42 (bs, 1H, NH), 5.29 (dd, 1H, J = 
15.3, 7.2 Hz, CHCH=), 5.25-5.11 (m, 3H, =CH2, CHOCO), 4.78 (s, 1H, CHOMe), 3.93 (d, 
1H, J = 8.8 Hz, CHHO), 3.86 (d, 1H, J = 8.8 Hz, CHHO), 3.39 (s, 3H, OCH3), 2.01 (q, 2H, J 
= 7.1 Hz, =CHCH2), 1.35-1.17 (m, 16H, C8H16), 0.87 (t, 3H, J = 6.8 Hz, CH3); 13C NMR 
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(101 MHz, CDCl3): δ 169.6, 158.4, 139.6, 136.2, 135.5, 129.3, 129.0, 127.3, 121.3, 117.0, 
82.4, 77.8, 71.7, 63.7, 57.4, 32.5, 32.0, 29.7, 29.7, 29.5, 29.4, 29.2, 28.8, 22.8, 14.2; IR (ATR, 
cm-1): 2923, 2853, 1748, 1169, 1108, 752; HRMS (ESI+) calculated for C27H40NO5 [M+H]+ 
= 458.2901, found = 458.2891. 
 
Typical procedure for hydrolysis of the (R)-MPA esters 8 to amino diols 9. 
A solution of ester (2S,3R)-8 (0.170 g, 0.372 mmol) in a 1:1 EtOH/2M aq. NaOH mixture (6 
mL) was heated to reflux. The progress of the reaction was followed by TLC (hexanes/AcOEt 
3:2). After 20 h, the EtOH was evaporated under vacuum and the aqueous residue was 
extracted with CH2Cl2 (4 x 10 mL). The combined organic portions were dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. The crude product was 
purified by column chromatography in silica gel (9:1 CH2Cl2/MeOH) to afford 0.099 g (0.35 
mmol, 94%) of (2S,3R)-9.  
(2S,3R)-9: colourless oil; [α]D25 = +14.4 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ 
5.97 (dd, 1H, J = 17.7, 10.7 Hz, CH=CH2), 5.74 (dt, 1H, J = 15.4, 6.7 Hz, =CHCH2), 5.45 
(dd, 1H, J = 15.4, 7.6 Hz, CHCH=), 5.33-5.24 (m, 2H, =CH2), 3.96 (d, 1H, J = 7.6 Hz, 
CHOH), 3.71 (d, 1H, J = 11.0 Hz, OCHH), 3.43 (d, 1H, J = 10.9 Hz, OCHH), 2.21 (bs, 4H, 
NH2, 2xOH), 2.04 (q, 2H, J = 7.2 Hz, =CHCH2), 1.44-1.14 (m, 16H, C8H16), 0.87 (t, 3H, J = 
6.8 Hz, CH3); 13C NMR (101 MHz, CDCl3): δ 140.0, 136.0, 127.7, 115.8, 77.0, 66.7, 60.7, 
32.5, 32.1, 29.8, 29.6, 29.5, 29.4, 29.4, 29.3, 22.8, 14.3; HRMS (ESI+) calculated C17H34NO2 
[M+H]+ = 284.2584, found = 284.2581. 
(2R,3S)-9: [α]D25 = –15.1 (c = 1.0, CHCl3); HRMS (ESI+) calculated C17H34NO2 [M+H]+ = 
284.2584, found = 284.2584. 
(2R,3R)-9: mp 63-5 ºC; [α]D25 = –7.0 (c = 1.1, CHCl3); 1H NMR (400 MHz, CDCl3): δ 5.82 
(dd, 1H, J = 17.7, 10.8 Hz, CH2=CH), 5.73 (dt, 1H, J = 15.2, 7.1 Hz, =CHCH2), 5.41 (dd, 1H, 
J = 15.4, 6.6 Hz, CHCH=), 5.31-5.25 (m, 2H, =CH2), 4.10 (d, 1H, J = 6.3 Hz, CHOH), 3.65 
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(d, 1H, J = 11.0 Hz, OCHH), 3.48 (d, 1H, J = 11.0 Hz, OCHH), 2.03 (q, 2H, J = 7.1 Hz, 
=CHCH2), 1.38-1.20 (m, 16H, C8H16), 0.88 (t, 3H, J = 6.9 Hz, CH3); 13C NMR (101 MHz, 
CDCl3): δ 138.6, 134.7, 127.5, 116.0, 75.6, 67.3, 61.3, 32.4, 32.1, 29.6, 29.5, 29.3, 29.3, 29.2, 
29.1, 22.7, 14.1; HRMS (ESI+) calculated C17H34NO2 [M+H]+ = 284.2584, found = 
284.2581. 
For (2S,3S)-9: [α]D25 = +7.6 (c = 1.0, CHCl3); HRMS (ESI+) calculated C17H34NO2 [M+H]+ 
= 284.2584, found = 284.2583. 
 
(3’S,4’R,E)-N-(4-hydroxy-3-(hydroxymethyl)hexadeca-1,5-dien-3-yl)octanamide (11) 
A solution of octanoic acid (7.2 mg, 0.05 mmol) and EDC (10 mg, 0.05 mmol) in anhydrous 
CH2Cl2 (1 mL) was stirred for 30 min. To this mixture, a solution of the starting alcohol 
(2S,3R)-9 (10 mg, 0.035 mmol) and DMAP (5 mg, 0.04 mmol) in CH2Cl2 (1 mL) was added 
dropwise. After stirring 15h at rt, the mixture was diluted with CH2Cl2 (5 mL) and washed 
successively with HCl 1N, water, NaHCO3 and water (3 mL each). The organic layer was 
dried over MgSO4, filtered and concentrated under reduced pressure. The resulting crude was 
purified by flash chromatography (Hexanes-EtOAc 8:2), to yield amide 10 (10.7 mg, 75%). 
1H NMR (400 MHz, CDCl3) δ 6.04 (br s, 1H, NH), 5.93 (dd, J = 17.3, 10.7 Hz, 1H, =CH), 
5.79 – 5.66 (m, 1H, =CHC10H21), 5.38 (ddd, J = 7.6, 7.0, 1.7 Hz, 1H, =CHCHOH), 5.24 (dd, J 
= 82.8, 14.0 Hz, 2H, =CH2), 4.45 (br s, 1H, CH2OH), 4.07 (d, J = 7.4 Hz, 1H, CHOH), 3.74 
(s, 1H, CHOH), 3.60 (ddd, J = 15.4, 12.0, 4.3 Hz, 2H, CH2OH), 2.31 – 2.24 (m, 2H, 
CH2C(O)), 2.04 (dd, J = 14.5, 7.0 Hz, 2H, =CHCH2), 1.65 (dt, J = 14.9, 7.6 Hz, 2H, CH2 
CH2C(O)), 1.45 – 1.17 (br m, 24H, C12H24), 0.88 (td, J = 6.8, 2.6 Hz, 6H, CH3). 13C NMR 
(101 MHz, CDCl3) δ 174.9 (C), 136.56 (CH), 136.3 (CH), 126.6 (CH), 116.17 (CH2), 74.7 
(CH), 66.9 (CH2), 66.0 (CH2), 37.3 (CH2), 32.5 (CH2), 32.0 (CH2), 31.8 (CH2), 29.8 (CH2), 
29.8 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 26.09 
21		
(CH2), 22.8 (CH2), 22.7 (CH2), 14.3 (CH3), 14.2 (CH3). HRMS (ESI+) calculated C25H47NO3 
[M+H]+ = 410,3634, found 410,3595.  
 
Biology 
Cell culture  
Human A549 lung adenocarcinoma cells were obtained from the American Type Culture 
Collection (ATCC) and grown in Ham’s F-12 medium supplemented with 10% fetal bovine 
serum (FBS), 1% Penicillin and Streptavidin and 2mM Glutamine at 37 ⁰C in 5% CO2/95% 
air.  
Cell viability of amide 11 
Cells were seeded in complete medium at 10.000 cells per well in 96-well plates. Twenty-four 
hours after seeding, media were replaced with fresh medium and compounds were added to 
give final concentrations of 0.02–400 µM. After 24 h, the number of viable cells was 
quantified by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. 
Vehicle (0.25 % methanol) was used in controls. The viability for amide 11 (expressed as 
IC50) ranged between 33 to 58 µM. 
 
Lipid analysis 
A549 cells were seeded in 1 mL of medium with 10% FBS-penicillin, streptavidin, glutamine 
in a 6-well plates (250.000 cells/well). Twenty-four hours later, media were replaced with 
fresh medium containing the compounds at the specified concentrations. After 24 h, the 
medium was removed and cells were washed in PBS, collected by brief trypsinization, 
transferred to Eppendorf vials and resuspended in 0.1 mL of PBS. An aliquot (0.01 mL) was 
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taken for cell counting. The remaining suspension was transferred to glass vials and 0.75 mL 
of chloroform/methanol (2:1) containing the internal standards (C17-sphinganine, N-
dodecanoylsphingosine, N-dodecanoylglucosylsphingosine and N-
dodecanoylsphingosylphosphorylcholine, 0.2 nmol each), were added. Samples were heated 
at 48 ºC overnight and 0.075 mL of 1 M KOH in methanol was added, followed by 2 h 
incubation at 37 ºC. Finally, the mixtures were neutralized with 0.075 mL of 1 M acetic acid, 
dried under nitrogen and the residue was dissolved in 0.150 mL of methanol. The liquid 
chromatography–mass spectrometer consisted of a Waters Aquity UPLC system connected to 
a Waters LCT Premier orthogonal accelerated time of flight mass spectrometer (Waters, 
Millford, MA), operated in positive or negative electrospray ionisation mode. Full scan 
spectra from 50 to 1500 Da were acquired and individual spectra were summed to produce 
data points each 0.2 s. Mass accuracy and reproducibility were maintained by using an 
independent reference spray via the LockSpray interference. The analytical column was a 100 
mm x 2.1 mm id, 1.7 µm C8 Acquity UPLC BEH (Waters). The two mobile phases were 
phase A: MeOH/H2O/HCOOH (74:25:1 v/v/v); phase B: MeOH/HCOOH (99/1 v/v), both 
also contained 5 mM ammonium formate. A gradient was programmed—0.0 min, 80% B; 3 
min, 90% B; 6 min, 90% B; 15 min, 99% B;18 min, 99% B; 20 min, 80% B. The flow rate 
was 0.3 mL·min-1. The column was held at 30 ºC. Quantification was carried out using the 
extracted ion chromatogram of each compound, using 50 mDa windows. The linear dynamic 
range was determined by injecting standard mixtures. Positive identification of compounds 
was based on the accurate mass measurement with an error <5 ppm and its LC retention time, 
compared to that of standards (±2%) 
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